[1]薛 达,王增国a,蒋恺憧b,等.百日咳重现下MRBp 感染的治疗、防控及面临的挑战[J].现代检验医学杂志,2024,39(04):1-4+22.[doi:10.3969/j.issn.1671-7414.2024.04.001]
　XUE Da,WANG Zengguoa,JIANG Kaichongb,et al.Treatment, Prevention and Challenges of MRBp Infection in the Resurgence of Pertussis[J].Journal of Modern Laboratory Medicine,2024,39(04):1-4+22.[doi:10.3969/j.issn.1671-7414.2024.04.001]
点击复制

百日咳重现下MRBp 感染的治疗、防控及面临的挑战()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
1-4+22
栏目:
述评
出版日期:
2024-07-15

文章信息/Info

Title:
Treatment, Prevention and Challenges of MRBp Infection in the Resurgence of Pertussis
文章编号:
1671-7414（2024）04-001-05
作者:
薛 达1; 王增国1; 2a; 蒋恺憧2b; 汤舒越1
（1. 陕西中医药大学，陕西咸阳712046；2. 西安市儿童医院 a. 检验科；b. 儿科疾病研究所，西安710002）
Author(s):
XUE Da1;  WANG Zengguo1; 2a;  JIANG Kaichong2b;  TANG Shuyue1
（1. Shaanxi University of Chinese Medicine, Shaanxi Xianyang 712046, China； 2a. Department of Clinical Laboratory；2b. Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an 710002, China）
关键词:
百日咳; 百日咳鲍特菌; 耐大环内酯类百日咳鲍特菌; 诊疗; 防控
分类号:
R516.6；R446.5
DOI:
10.3969/j.issn.1671-7414.2024.04.001
文献标志码:
A
摘要:
百日咳（whooping cough）是由百日咳鲍特菌（Bordetella pertussis，Bp）感染，通过空气传播的急性呼吸道传染病。大环内酯类抗生素（Macrolides antibiotics）一直是治疗百日咳的首选药物。但自从国内首次报道耐大环内酯类百日咳鲍特菌（Macrolide-resistant Bordetella pertussis，MRBp）后，近年来我国出现了MRBp 的广泛流行。尤其近期全球百日咳重现，深入了解MRBp 流性特征、诊疗、防控进展及面临的挑战尤为重要。
Abstract:
Whooping cough，caused by Bordetella pertussis (Bp) infection, is an acute respiratory infectious disease in children transmitted through the air．Macrolide antibiotics have long been the first-line treatment for whooping cough．However，in recent years，macrolide-resistant Bordetella pertussis (MRBp) has been rarely reported outside China．The high prevalence of MRBp in China adds to the global challenge of whooping cough resurgence. The research firstly reports the emergence of clinical MRBp strains in China and has conducted extensive research in this field．This paper focuses on discussing the progress and challenges in the diagnosis, treatment and prevention of MRBp based on historical and recent studies.

参考文献/References:

[1] MATTOO S, CHERRY J D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies[J]. Clinical Microbiology Reviews, 2005, 18(2): 326-382.
[2] FENG Ye, CHIU C H, HEININGER U, et al. Emerging macrolide resistance in Bordetella pertussis in mainland China: findings and warning from the global pertussis initiative [J]. The Lancet Regional Health Western Pacific, 2021, 8: 100098.
[3] TIWARI T, MURPHY T V, MORAN J，et al. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines [J]. Morbidity and Mortality Weekly Report, 2005, 54(RR-14):1-16.
[4] PLOTKIN S, ORENSTEIN W, OFFIT P, et al. Plotkin’s vaccines[M]. 7th Ed. Philadelphia: Elsevier Press, 2017.
[5] MERDRIGNAC L, AYT ELBELGHITI F, PANDOLFI E, et al. Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019 [J]. Vaccine, 2024 , 42(9):2370-2379.
[6] CHERRY J D. The 112-year odyssey of pertussis and pertussis vaccines-mistakes made and implications for the future [J]. Journal of the Pediatric Infectious Diseases Society, 2019, 8(4): 334-341.
[7] WANG Z, CUI Z, LI Y, et al. High prevalence of erythromycin-resistant Bordetella pertussis in Xi’an, China[J]. Clinical Microbiology and Infection , 2014, 20(11): O825-O830.
[8] IVASKA L, BARKOFF A M, MERTSOLA J, et al. Macrolide resistance in Bordetella pertussis: current situation and future challenges[J]. Antibiotics, 2022, 11(11): 1570.
[9] GUILLOT S, DESCOURS G, GILLET Y, et al. Macrolide-resistant Bordetella pertussis infection in newborn girl, France[J]. Emerging Infectious Diseases, 2012, 18(6): 966.
[10] SHAHCHERAGHI F, NAKHOST LOTFI M, NIKBIN V S, et al.The first macrolide-resistant Bordetella pertussis strains isolated from Iranian patients [J]. Jundishapur Journal of Microbiology ,2014,7(6):e10880.
[11] YAO Kaihu, DENG Jikui, MA Xiang, et al. The epidemic of erythromycin-resistant Bordetella pertussis with limited genome variation associated with pertussis resurgence in China [J]. Expert Review of Vaccines, 2020, 19(11): 1093-1099.
[12] WANG Zengguo, LI Yarong, HOU Tiejun, et al. Appearance of macrolide-resistant Bordetella pertussis strains in China [J]. Antimicrobial Agents and Chemotherapy, 2013, 57(10): 5193-5194.
[13] KOIDE K, YAO Shuman, CHIANG C S, et al. Genotyping and macrolide-resistant mutation of Bordetella pertussis in east and south-east Asia [J]. Journal of Global Antimicrobial Resistance, 2022, 31: 263-269.
[14] YAMAGUCHI T, KAWASAKI Y, KATSUKAWA C, et al. The first report of macrolide-resistant Bordetella pertussis isolation in Japan [J]. Japanese Journal of Infectious Diseases, 2020,73(5):361-362.
[15] XU Zheng, WANG Zengguo, LUAN Yang, et al. Genomic epidemiology of erythromycin-resistant Bordetella pertussis in China[J]. Emerging Microbes & Infections, 2019, 8(1): 461-470.
[16] FU Pan, ZHOU Jinlan, MENG Jianhua, et al. Emergence and spread of MT28 ptxP3 allele macrolideresistant Bordetella pertussis from 2021 to 2022 in China [J]. International Journal of Infectious Diseases, 2023, 128: 205-211.
[17] CAI Jiehao, CHEN Mingliang, LIU Qiyi, et al. Domination of an emerging erythromycin-resistant ptxP3 Bordetella pertussis clone in Shanghai, China [J]. International Journal of Antimicrobial Agents, 2023, 62(1): 106835.
[18] WU Xiaoying, DU Qianqian, LI Dongfang, et al. A cross-sectional study revealing the emergence of erythromycin-resistant Bordetella pertussis carrying ptxP3 alleles in China [J]. Frontiers in Microbiology, 2022, 13: 901617.
[19] FU Pan, ZHOU Jinlan, YANG Chao, et al. Molecular evolution and increasing macrolide resistance of Bordetella pertussis, Shanghai, China, 2016-2022 [J]. Emerging Infectious Diseases, 2023, 30(1): 29-38.
[20] MIRZAEI B, BAMERI Z, BABAEI R, et al. Isolation of high level macrolide resistant Bordetella pertussis without transition mutation at domain V in Iran [J]. Jundishapur Journal of Microbiology, 2015, 8(7): e18190.
[21] MERTSOLA J, KURONEN T, TURUNEN A, et al. Diagnosis of pertussis [J]. Journal of Infection, 1984, 8(2): 149-156.
[22] WANG Zengguo, HAN Ruijun, LIU Ying, et al. Direct detection of erythromycin-resistant Bordetella pertussis in clinical specimens by PCR [J]. Journal of Clinical Microbiology, 2015, 53(11): 3418-3422.
[23] 吴小英, 李丽君, 姚开虎, 等. 儿童重症百日咳治疗策略研究进展[J]. 中国当代儿科杂志, 2021,23(2):192-197. WU Xiaoying, LI Lijun, YAO Kaihu, et al. Research advances in the treatment strategies for severe pertussis in children[J]. Chinese Journal of Contemporary Pediatrics, 2021, 23(2):192-197.
[24] 中华医学会感染病学分会儿科感染学组, 国家卫生健康委能力建设和继续教育儿科专委会感染组,中国临床实践指南联盟方法学专委会, 等. 中国百日咳诊疗与预防指南(2024 版)[J]. 中华医学杂志,2024, 104(15)：1258-1279. Pediatric Infection Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Infection Group, Pediatric Expert Committee of National Health Commission Capacity Building and Continuing Education, China Clinical Practice Guidelines Alliance Methodology Committee，et al. Guidelines for diagnosis and management and prevention of pertussis of China (2024 edition) [J]. National Medical Journal of China, 2024, 104(15): 1258-1279.
[25] 国家卫生健康委办公厅，国家中医药局综合司．百日咳诊疗方案（2023 年版）[EB/OL](2023-12-28)[2024-04-10]. htpp：//www.nhc.gov.cn/ylyjs/pqt/202312/75cfff021a484d0c9c200f85f2bf746b/files/f732266b89ab427289ab37b886158a1c.pdf. National Health Commission of the People’s Republic of China ，State Administration of Traditional Chinese Medicine. Diagnosis and treatment plan for pertussis (2023 edition) [EB/OL](2023-12-28)[2024-04-10]. htpp://www.nhc.gov.cn/ylyjs/pqt/202312/75cfff021a484d0c9c200f85f2bf746b/files/f732266b89ab427289ab37b886158a1c.pdf.
[26] 中华医学会儿科学分会感染学组,《中华儿科杂志》编辑委员会. 中国儿童百日咳诊断及治疗建议[J].中华儿科杂志, 2017, 55(8):568-572. The Subspecialty Group of Infectious Diseases, The Society of Pediatrics, Chinese Medical Association, The Editorial Board of Chinese Journal of Pediatrics. Recommendation for diagnosis and treatment of Chinese children with pertussis[J]. Chinese Journal of Pediatrics, 2017, 55(8):568-572.
[27] HOPPE J E. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis[J].Infection, 1998，26(4):242-246.
[28] LI Yarong, LIU Xiaoguai, ZHANG Bei, et al. Where macrolide resistance is prevalent [J]. Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 2015, 123(4): 361-363.
[29] HUA Chunzhen, WANG Hongjiao, ZHANG Zhe, et al. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillintazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: a single-centre study in Zhejiang Province, China [J]. Journal of Global Antimicrobial Resistance, 2019, 18: 47-51.
[30] MI Yumei, HUA Chunzhen, FANG Chao, et al. Effect of macrolides and β-lactams on clearance of Bordetella pertussis in the nasopharynx in children with whooping cough [J]. The Pediatric Infectious Disease Journal, 2021, 40(2): 87-90.
[31] 林江涛, 张永明, 王长征, 等. 大环内酯类药物的抗菌外作用与临床应用专家共识[J]. 中华内科杂志,2017, 56(7):546-557. LIN Jiangtao, ZHANG Yongming, WANG Changzheng, et al. Chinese expert consensus for nonantiinfective effects and clinical use of macrolides[J]. [J]. Chinese Journal of Internal Medicine, 2017, 56(7): 546-557.
[32] ASADI L, SLIGL W I, EURICH D T, et al. Macrolidebased regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis [J]. Clinical Infectious Diseases, 2012, 55(3): 371-380.
[33] L? Zhe，YIN Sha，JIANG Kaichong，et al. The whole-cell proteome shows the characteristics of macrolides-resistant Bordetella pertussis in China linked to the biofilm formation [J]. Archives of Microbiology, 2023, 205(6): 219.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金委员会（8217081223）。
作者简介：薛达（1998-），男，硕士在读，研究方向：传染病流行病学与实验诊断学，E-mail：a1095255605@icloud.com。
通讯作者：王增国（1981-），男，博士，主任技师，E-mail：william_wzg@126.com。
更新日期/Last Update: 2024-07-15